- US-based Clinipace Inc. acquires Accovion GmbH, Frankfurt
- Combined company has operations in 39 countries and employs nearly 1,000 staff
- Accovion CEO will head Clinipace’ European operations
Heidelberg / Bad Homburg, April 13, 2015 – The independent Private Equity firms HeidelbergCapital and Creathor Venture together with former and current management and employees have sold their shares in Accovion GmbH, a leading European full-serviceContract Research Organization (CRO), headquartered in Frankfurt (Eschborn), Germany to US-based Clinipace Inc., a global digital Contract Research Organization (dCRO).
Dr. Clemens Doppler, Managing Partner of HeidelbergCapital: “Accovion with its pan-European footprint, best known for its team of highly qualified and motivated specialists and strive for high quality results in drug approvals and upmost customer satisfaction will become an integral part of the Clinipace’s worldwide operations.” “The combination of the two companies will further accelerate their growth and increase their service offerings for customers worldwide”, adds Karlheinz Schmelig,Managing Partner of Creathor Venture.
“We are pleased to join the Clinipace Worldwide organization,” says Dr. Andree Beckerling, the CEO of Accovion. “With the strong strategic alignment between Clinipace’s and Accovion’s capabilities, objectives and values, I am confident that Clinipace Worldwide is a great fit for our continued commitment to quality, reliability and flexibility.”
The addition of Accovion to its group of companies enables ClinipaceWorldwide to improve its value proposition for the European market by significantly expanding its European geography and establishing all of the full-service clinical development and regulatory needs within local time zones via an integrated European unit with an excellent reputation and broad expertise.
Dr. Beckerling will have day-to-day operating responsibility for all of the European offices, including existing Clinipace staff and locations. Together, Accovion and ClinipaceWorldwide will now be home to nearly 400 staff in Europe and nearly 1,000 globally. The combined company has managed over 3,000 clinical research studies and more than 300 regulatory and strategic development engagements.
Together with Accovion, the combined organization has operations and staff in 39 countries. European operations are based in Frankfurt, Munich and Marburg, Germany; Prague, Czech Republic; Krakow, Poland; Timisoara, Romania; Moscow, Russia; Zurich, Switzerland; Milan, Italy; Lyon, France; Madrid, Spain; London, United Kingdom and Kiev,Ukraine.
The Sellers were advised by KMPG AG (Florian Frei & Konrad Hinkens) and Dechert LLP